Hepatitis B

FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.

Data Elements

DEMOGRAPHICS

Diagnosis
Age
Gender
Race / Ethnicity
BMI
Height / Weight
Genotype
Fibrosis Score

LABS

CBC
ALT / AST
HBV Viral Load
Serum Creatinine
eGFR
HbA1c
HBeAg, HBeAb
APRI score
Bone Density

PRIOR HISTORY

Prior Treatment Status
Prior Treatment Regimen
Duration of Therapy
Reason for Failure
Prior Transplant
Smoking Status
Illicit Drug Use

COMORBIDS

HIV Coinfection
Anxiety
Depression
Hypertension
Diabetes
Chronic Kidney Disease
Hyperlipidemia
Hemodialysis

PROVIDERS

Type (Physician, NP, PA)
Specialty
Academic vs Community
Specialty Pharmacy

PAYERS

Type (Commercial, Medicare, Medicaid, Dual Eligible)
Payer Name
Self-Pay and Patient Assistance
Eligibility
Correct PA form
Denial Reason

PA TIMELINE

PA Submitted Date
Approval / Denial Date
Appeals Submitted

DISPENSING INFO

Current Treatment Regimen Rx
Intended Regimen
Actual Regimen
Duration
Dispensed Regimen
Gaps in Therapy

Publications

2019

Clinical Practice Experience with Tenofovir Alafenamide (TAF) for Treatment of Hepatitis B in the US

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Janna Radtchenko, and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019

Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019

Effectiveness and Safety with Tenefovir Alafenamide (TAF) for Hepatitis B in Patients of Asian Race in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz and Nezam Afdhal

Oral Presented at: Asian Pacific Association for the Study of the Liver (APASL)

Conference dates: February 20, 2019 - February 24, 2019

2018

Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice: Real-World Evidence from the TRIO Network

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018

Treatment of Hepatitis B in the US: Real-World Evidence from the TRIO Network

Ho Bae, Michael Curry, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 9, 2018 - November 13, 2018

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi and Nezam Afhdal

Poster Presented at: Digestive Disease Week (DDW)

Conference dates: June 2, 2018 - June 5, 2018

Hepatitis B

Hepatitis B

​FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.

Data Elements

DEMOGRAPHICS

LABS

PRIOR HISTORY

COMORBIDS

PROVIDERS

PAYERS

PA TIMELINE

DISPENSING INFO

Publications

2019

Clinical Practice Experience with Tenofovir Alafenamide (TAF) for Treatment of Hepatitis B in the US

Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice

Effectiveness and Safety with Tenefovir Alafenamide (TAF) for Hepatitis B in Patients of Asian Race in US Clinical Practice

2018

Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice: Real-World Evidence from the TRIO Network

Treatment of Hepatitis B in the US: Real-World Evidence from the TRIO Network

Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network

FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARAMACIES WITHOUT BIAS.